Pioglitazone in triple therapy

The licence for Actos (pioglitazone) has been extended to include triple oral therapy in combination with metformin and a sulphonylurea in patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy.

Previously, Actos was licensed only as monotherapy or as dual therapy in combination with either metformin or a sulphonylurea.

The recommended dose of pioglitazone is the same whether used in montherapy or dual or triple combination therapy. Treatment should be started at 15-30mg once daily increasing to 45mg once daily if necessary in combination with metformin and/or a sulphonylurea.

Common adverse effects associated with triple therapy include weight gain, increased creatine phosphokinase, arthralgia and hypoglycaemia.
Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases